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Abstract NeuroAIDS persists in the era of combination 
antiretroviral therapies. We describe here the recovery of 
brain structure and function following 6 months of 
therapy in a treatment-naive patient presenting with 
HIV-associated dementia. The patient's neuropsycholog-
ical test performance improved and his total brain vol-
ume increased by more than 5 %. Neuronal functional 
connectivity measured by magnetoencephalography 
changed from a pattern identical to that observed in 
other HIV-infected individuals to one that was indistin-
guishable from that of uninfected control subjects. 
These data suggest that at least some of the effects of 
HIV on the brain can be fully reversed with treatment. 
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Introduction 
In spite of changes in the treated history of HIV disease 
following the introduction of combination therapies (cART), 
there have been few detailed descriptions of the recovery of 
brain structure and function that occur following treatment 
initiation. We describe here a 54-year-old man who first 
presented for treatment with HIV-associated dementia 
(HAD), neuropathy, and myelopathy who had significant 
recovery documented with neurobehavioral exams, brain 
structural data from magnetic resonance imaging (MRI), 
and functional connectivity of neuronal networks using 
magnetoencephalography (MEG). 
Methods 
Case summary 
PG is a 54-year-old, high school-educated, right-handed 
African American man who was admitted to a local hospital 
and diagnosed with Pneumocystis jirovecii pneumonia and 
found to be HIV-infected. His family learned that he was 
unable to live independently, that he had been fired from his 
job, and that he had been evicted from his apartment due to 
memory loss, confusion, and the inability to care for himself. 
PG moved to live with his extended family and to establish 
care with an HIV specialty clinic (March 2010). At that time, 
they reported that he was confused, having problems with 
both short- and long-term memory, and was unsteady on his 
feet, resulting in several falls. He had lost 40 lb over 5 months. 
His CD4+ count in March 2010 was 12 cells/mm3 (1 %), 
with an HIV-1 RNA level of 638,000 copies per milliliter 
(logio=5.80); therapy was started using the daily fixed-dose 
combination of efavirenz-emtricitabine-tenofovir. He returned 
to the clinic 1 month later, at which time both he and his family 
reported that he was functioning more independently. His 
CD4+ count was 236 cells/mm3 (8 %), and the HIV-1 RNA 
level was 7,510 copies per milliliter (logio=3.88). In May 
2010, his viral load was 412 (logio=2.61), he was more inde-
pendent, and he was inteimittently using a cane to ambulate. 
A clinical neuropsychological assessment was completed 
in May 2010 that revealed evidence of HAD, including 
moderate to severe deficits in cognitive functions. He was 
approached by his treating physician about his willingness 
to participate in a study of the utility of MEG as a biomarker 
in HIV disease. He consented to enroll and his data were 
compared with that of nine HIV-infected individuals and 
seven uninfected control subjects. With the exception of 
the Executive Domain Rating score from the neuropsychol-
ogy test battery, there were no significant differences be-
tween the two comparison groups (HIV-positive vs. HIV-
negative), so the data from all 16 participants were combined. 
The mean age (50.2±5.0) and education level (14.7± 1.9) 
compared well with PG. 
Procedures 
Cognitive/Behavioral Evaluation 
A neuropsychological examination was completed in May 
2010, and again 6 months later, and included measures from 
multiple cognitive domains including memory, language, 
visual construction, psychomotor speed, motor and execu-
tive functions. PG underwent a semi-structured diagnostic 
interview and completed questionnaires concerning psychi-
atric symptomatology (see Becker et al. 2012a for details). 
MRI study 
PG had an MRI exam of the brain on a Siemens 3T TIM 
Trio using a protocol that was modified from that of the 
Alzheimer's Disease Neuroimaging Initiative (Mueller et al. 
2005). The parameters of the sagittal magnetization pre-
pared rapid acquisition gradient echo sequence were: 
FOV=256 mm; slices=160; TR=2,300 ms; TE=2.91 ms; 
TI=900 ms; flip angle=9°; slice thickness=1.2 mm. The 
MRI data were processed using SIENA, a fully automated 
method to measure the change between two MR images 
taken at different time points (Smith et al. 2002). The output 
from SIENA is the mean perpendicular edge motion across 
the entire brain surface converted into a percentage brain 
volume change estimate. 
Magnetoencephalography 
Elekta Neuromag© Vectorview (Elekta Oy, Helsinki, 
Finland) uses 306 MEG channels for registering the neuro-
magnetic signatures of the intracranial neural currents. The 
MEG acquisition included 5 min of "eyes open" and 5 min 
of "eyes closed" resting state; for this report, we analyzed 
only the eyes closed data as there were fewer artifacts (e.g., 
eye blinks) compared to the eyes open data. The MEG 
procedures and data preprocessing are detailed elsewhere 
(Becker et al. 2012a). 
The MEG data were filtered on-line to 0.1-330 Hz and 
sampled at 1 kHz. For analysis, we filtered the data to 0.1-60 Hz 
and calculated the mutual information (MI) (Hlavackova-
Schindler et al. 2007) between the 102 sensor units (magneto-
meters and gradiometers), which gave us a symmetric and 
weighted correlation matrix of 102x102 elements for each 
analysis. We computed an "MI score" by taking the mean MI 
between the two groups of sensors where we have previously 
found significant statistical differences in the gradiometers 
(see Fig. lb; Becker et al. 2012b). 
Results 
The change in PG's test scores over the 6-month interval 
was compared with the change observed in the comparison 
group (see Table 1). Significant improvements were 
observed on tasks of cognitive and motor speed; there were 
no significant changes in his performance on measures of 
either learning or memory. 
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Fig. 1 a Results of the SIENA analysis {upper panel). The images 
show the changes in brain surface over the course of 6 months {top 
row, sagittal plane; bottom row, coronal row). Expansion of the brain 
(indicated in yellow and red) indicates a narrowing of the sulci (i.e., 
widening of the gyri) as well as shrinkage of the ventricles, b The 
results of the analysis of the MEG data are shown in the lower panel. 
Subject Number 
On the left is a graph of the functional network that maximally differ-
entiated HIV-infected from HIV-uninfected individuals. On the right is 
a graph of the MI score for each individual subject. The green circles 
indicate uninfected participants in the comparison group; the red 
circles indicate HIV-infected participants. The MI score for PG is 
shown as two points connected by a line 
Table 1 Change in neuropsy-
chological test performance in 
PG 
aMeans and standard deviations 
of age, education, sex- and race-
adjusted T scores (Heaton and 
Taylor 2004) 
brndividual J scores for each per-
formance measure 
°Z-scores and/; values of differ-
ence between predicted change 
(from comparison group) and 
that of PG (Crawford et al. 2010) 
Median and range of domain 
scores; n.b., higher scores (i.e., 5-
9) indicate impaired performance 
Domain/measure 
Fluency 
Letters 
Animals 
Domain score 
Executive 
Trail making B 
Domain score 
Speed of processing 
Digit symbol substitution 
Trail making A 
Domain score 
Spatial skills 
Block design 
Domain score 
Learning 
HVLT-TR 
Domain score 
Memory 
HVLT delay 
Domain score 
Motor 
Grooved pegboard 
Domain score 
Global impairment rating 
Comparison 
Baseline 
54.4 (8.4) 
57.5 (9.4) 
2 ( l -4) d 
67.3(11.2) 
2 (1-4) 
53.5 (9.3) 
73.2(11.4) 
1 (1-3) 
59.8 (9.2) 
1 (1-5) 
49.3 (12.8) 
2 (1-9) 
46.5 (13.3) 
2 (1-9) 
56.2 (8.7) 
1 (1-5) 
4 (1-9) 
group3 
Follow-up 
54.1 (8.9) 
57.1 (8.9) 
2 ( l -4) d 
64.4 (13.4) 
1 (1-5) 
54.2 (9.0) 
70.1 (11.7) 
2 (1-4) 
61.6(12.7) 
1 (1-3) 
51.3 (8.8) 
2 (1-7) 
51.6(8.5) 
2 (1-7) 
54.6 (8.0) 
2 (1-2) 
4 (1-7) 
Patient PGb 
Baseline 
36 
43 
5 
31 
6 
31 
21 
8 
25 
7 
20 
8 
20 
8 
29 
7 
9 
Follow-up 
54 
58 
2 
43 
4 
39 
42 
4 
33 
6 
32 
6 
23 
8 
46 
2 
8 
Statistics0 
Z score 
2.29 
1.90 
1.29 
-0.25 
1.46 
2.67 
0.85 
-0.22 
2.61 
P 
.02 
.04 
.07 
.12 
.02 
.03 
.46 
.07 
.02 
The neuropsychological test data were reduced to domain 
and global ratings of performance based on standardized 
and normative procedures (Woods et al. 2004). The scores 
have a range from 1 (superior) to 9 (severely impaired); 1-3 
is considered normal, 4 is considered borderline, and scores 
of 5 and greater are considered abnormal. With the excep-
tion of the memory and learning ratings, his test perfor-
mance improved from impaired to borderline and normal 
after 6 months of cART (see Table 1). 
The mean change in whole brain volume in the comparison 
group was -0.29 % (SD=0.97). The percent change in brain 
volume in PG was 5.87 % (i.e., an increase in volume), which 
is significantly greater than that expected based on the com-
parison group (Z=6.36; see Fig. la). There is evidence 
of both expansion of gray matter (indicated in yellow 
and red in Fig. 1), reduction of ventricular volume, and 
widening of the gyri. 
Figure lb presents the results of the analysis of the MEG 
data. The left-hand graphs show the functional connectivity 
"map" between the MEG sensors; the right-hand graphic 
shows the MI score for each subject—PG and the compar-
ison group. The MI score for PG is shown as two points 
connected by a line. As can be seen from this figure, his MI 
score at baseline was near the mean for the infected partic-
ipants, while at the end of 6 months, his score had changed 
to a value close to the mean of the uninfected individuals. 
Discussion 
In spite of the declining incidence of HAD (Sacktor et al. 
2001), cognitive dysfunction persists even with the use of 
cART (Sacktor et al. 2002). Severe immunosuppression is 
not a requirement for HAD (Dore et al. 1999). Undetectable 
CSF HIV does not prevent the progression of disease 
(Cysique et al. 2005), and even with effective viral suppres-
sion, there is a high rate of the milder forms of HIV-
associated neurocognitive disorders (Simioni et al. 2010). 
These studies report group-level data; ours is one of the few 
reports of recovery of function among individuals diag-
nosed with HAD who had detailed cognitive testing, 
MR imaging, as well as an analysis of neuronal func-
tional connectivity using MEG. 
PG had virtual elimination of viral replication in the 
periphery (<50 copies at second visit) as well as a significant 
improvement in his CD4+ cell counts. His performance on 
the neuropsychological tests improved, and his overall brain 
volume increased more than 5 % with gyral widening and a 
reduction in the size of the lateral ventricles. What was most 
striking, however, was the "normalization" of his neuro-
magnetic signature. The MI score derived from the func-
tional connectivity analysis of the MEG data reflects the 
extent to which the neuronal populations near the sensor 
nodes were functionally connected and differentiated 
infected from uninfected individuals. Over the course of 
treatment, his MI score changed from one that was virtually 
identical to that of other infected subjects to one that was 
indistinguishable from the uninfected controls, suggesting 
that CNS function was returning to normal. 
With one exception, the HIV-infected individuals includ-
ed in the comparison group had been infected for at least 
10 years, had endured periods of uncontrolled viral replica-
tion, and had survived long enough to enjoy the benefits of 
cART. We speculate that the long-term uncontrolled or 
poorly controlled viral replication in the brain may have 
resulted in a permanent alteration in the functional net-
works, which is reflected in the MEG signature. PG's data 
suggest the possibility that all of the HIV-infected individ-
uals in the comparison group at one time had the potential to 
have their functional connectivity return to normal, if effec-
tive therapy had been available to them. 
In summary, we report the changes in CNS structure and 
function that occurred in a patient whose initial presentation 
and AIDS-defining illnesses included HAD following effec-
tive viral suppression. The recovery included a normaliza-
tion of a functional brain network identified with MEG 
imaging, suggesting that MEG may be a useful tool in 
monitoring response to HIV therapeutics (Price et al. 2007). 
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